Unlock 30% off global market reports with code ONLINE30 – get insights on tariff changes, macro trends, and global economic shifts
How has the gene editing market size changed in recent years, and what is the outlook ahead?
The gene editing market size has grown rapidly in recent years. It will grow from $8.82 billion in 2024 to $10.34 billion in 2025 at a compound annual growth rate (CAGR) of 17.3%. The growth in the historic period can be attributed to discovery of crispr-cas9, advancements in genetic sequencing, medical breakthroughs, scientific research funding, biotechnology industry growth.
The gene editing market size is expected to see rapid growth in the next few years. It will grow to $20.79 billion in 2029 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to therapeutic applications expansion, precision and efficiency enhancements, gene therapy commercialization, agricultural applications development, regenerative medicine growth. Major trends in the forecast period include multiplex editing techniques, base editing innovations, gene drives and population modification, non-viral delivery systems, disease modeling and drug discovery.
Download Your Free Sample PDF:
What are the top economic and technological drivers pushing gene editing market growth?
The gene editing market is being propelled by the increasing prevalence of communicable diseases, making gene editing techniques crucial for their detection and treatment. Communicable diseases are illnesses caused by infectious agents, such as bacteria, viruses, or parasites, that can be transmitted from person to person, animals, or the environment. Gene editing technologies are increasingly being leveraged to develop targeted approaches that can identify and combat pathogens at the genetic level, enhancing disease management and prevention efforts. For instance, in 2023, according to the World Economic Forum, a Switzerland-based international non-governmental organization, infections such as influenza and respiratory syncytial virus (RSV) have increased since the pandemic. In the USA, an estimated 24 million illnesses, 260,000 hospitalizations and 16,000 deaths from the influenza have occurred as of February 2023. Additionally, in 2022, according to the World Health Organization, 10.6 million people were infected with tuberculosis globally, with 1.3 million deaths attributed to tuberculosis. Therefore, communicable diseases are boosting gene editing market.
How is the gene editing market segmented by product, application, and end-user?
The gene editing market covered in this report is segmented –
1) By Technology: CRISPR, TALEN, ZFN
2) By Application: Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering
3) By End Users: Biotechnology, Pharmaceutical, Contract Research Organization
Subsegments:
1) By CRISPR: CRISPR-Cas9, CRISPR-Cas12, CRISPR-Cas13, CRISPR-based Gene Drives
2) By TALEN (Transcription Activator-Like Effector Nucleases): Custom TALENs, Commercial TALEN Kits
3) By ZFN (Zinc Finger Nucleases): Custom ZFNs, Commercial ZFN Kits
View The Full Market Report:
What evolving trends are creating new opportunities in the gene editing market?
Major companies operating in the gene editing markets are introducing innovative technology in gene editing, such as a technique based on special cell-penetrating peptides that promises advantages over current methods, to gain a competitive edge in the market. The approach could also power the development of advanced cell therapies for cancer and other diseases. For instance, in April 2023, Penn Medicine, a US-based major multi-hospital health system, found that protein fragments used by some viruses to help them get into cells could also be used to get CRISPR-Cas gene editing molecules into cells and their DNA-containing nuclei with extraordinarily high efficiency and low cellular toxicity. The scientists expect the new technique to be particularly useful for modifying T cells and other cells from a patient’s own body to make cell therapies. One such application could be CAR T (chimeric antigen receptor T cell) therapy, which uses specially modified immune cells from a patient to treat cancer. A new approach to the genetic engineering of cells promises significant improvements in speed, efficiency, and reduction in cellular toxicity compared to current methods.
Which leading companies are dominating the gene editing market landscape?
Major companies operating in the gene editing market include AstraZeneca plc, Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare Life Sciences, Agilent Technologies Inc., Lonza Group AG, PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., CRISPR Therapeutics, Promega Corporation, GenScript USA Inc., Integrated DNA Technologies Inc., Intellia Therapeutics Inc., DNA Script Inc., Dharmacon Inc., Precision Biosciences Inc., Editas Medicine Inc., OriGene Technologies Inc., Tecan Group Ltd., Sangamo Therapeutics Inc., Horizon Discovery Group plc, Addgene Inc., New England Biolabs Inc., Cellectis SA, Recombinetics Inc., Allele Biotechnology LLC, Transposagen Biopharmaceuticals Inc., Bluebird Bio Inc., Regeneron Pharmaceuticals Inc., Amsbio LLC, Creative Biogene Inc., Synthego Corporation, Beam Therapeutics Inc., Caribou Biosciences Inc., Inscripta Inc., Mammoth Biosciences Inc., Sangon Biotech (Shanghai) Co. Ltd., ToolGen Inc., Mirus Bio LLC
Which geographic areas are expected to offer the highest growth opportunities in thegene editing market?
North America was the largest region in the gene editing market in 2024. Western Europe was the second largest region in the global gene editing market share. The regions covered in the gene editing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Gene Editing Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
Need Customized Data On Gene Editing Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you're entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment